Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study29.4.2025 10:00:00 EEST | Acousia Therapeutics GmbH | Press release
Tübingen, Germany, April 29, 2025 Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and is used annually in more than 500,000 cancer patients worldwide. Its introduction in the late 1970s revolutionized testicular cancer treatment, improving the 5-year survival rate (from just 5% to 98%). However, its life-saving efficacy is often overshadowed by severe side effects, with permanent, bilateral hearing loss among the most debilitating. Studies indicate that up to 80% of patients treated with cisplatin may experience clinically-relevant hearing loss. The PROHEAR Study is a placebo-controlled, randomized, double-blind, split-body trial in which participants receive ACOU085, a Kv7.4 channel activator, in o